Human Genome Sciences, Inc.

Washington University

Daniel P Bednarik

Craig A Rosen

Henrik S Olsen

Steven M Ruben

Jian Ni

Guo-Liang Yu

Mark D Adams

Reinhard Ebner

Daniel R Soppet

Ann MeeJin Ferrie

Paul E Young

John M Greene

Yanggu Shi

Jing-Shan Hu

Gregory A Endress

Ping Feng

Laurie A Brewer

Kimberly A Florence

Roxanne Duan

Kenneth C Carter

Carrie L Fischer

David M Hilbert

Robert D Schreiber

David M Parmelee

Bernadetta Nardelli

Marianne Murphy

Ann Gronowski

The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein. IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are futher provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists.

Soluble interleukin-1 receptor accessory molecule

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Secreted protein HRGDF73

The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are further provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists.

A human HPRT-2 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of nephrolithiasis, anemia, precocious gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria. Antagonists against such polypeptides and their use as a therapeutic to treat disorders associated with excessive purine synthesis are also disclosed. Diagnostic assays for identifying mutations in nucleic acid sequences encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

Human hypoxanthine-(guanine) phosphoribosyl transferase-2

A human HPRT-2 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of nephrolithiasis, anemia, precocious gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria. Antagonists against such polypeptides and their use as a therapeutic to treat disorders associated with excessive purine synthesis are also disclosed. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

Human hypoxanthine- (guanine) phosphoribosyl transferase-2

Secreted protein HODAZ50

This invention relates to the use of the baculovirus glycoprotein, Interferon Stimulating Protein (ISP) (also known as gp67, gp64 EFP, or gp64), or the gene sequence encoding ISP, to stimulate production of interferon, such as for immunotherapy, anti-viral, anti-cancer, anti-bacterial, or anti-parasitic therapy. This invention also relates to novel mutant forms of ISP that show enhanced biological (i.e., anti-viral) activity, increased stability, higher yield or better solubility.

Interferon stimulating protein and uses thereof

Growing community of inventors

Columbia, MD, United States of America

Daniel P Bednarik